Predictors of Benzodiazepine Discontinuation in Subjects Manifesting Complicated Dependence
The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Abstract
We described characteristics of subjects with benzodiazepine dependence that was typically complicated by harmful and hazardous alcohol use or high benzodiazepine doses, and assessed predictors of successful discontinuation of benzodiazepines for this group. Seventy-six patients who participated in a randomized clinical trial of two different gradual withdrawal treatment approaches were assessed. The trial was conducted between February 1995 and July 1999. The mean age +/- SD of subjects was 40.0 +/- 9.6 years, 55% were male, 38% were married or cohabiting, and 70% had received more than nine years of education. The median benzodiazepine dose was 35 mg/day (range 2.5-180) in diazepam equivalents. The median duration of benzodiazepine use was 84 (range 8-360) months. Subjects with lower benzodiazepine doses and no previous withdrawal attempts were more successful at benzodiazepine discontinuation. Cluster B personality/borderline personality disorder was associated with an inability to stop benzodiazepine use and with "dropping out" of treatment. Alcohol use-related disorders or other psychiatric diagnoses were not associated with outcome. Further studies on predictors of successful benzodiazepine discontinuation in different populations are required. Patients manifesting cluster B personality/borderline personality disorder and benzodiazepine dependence may need concomitant treatment for their personality disorders to benefit from benzodiazepine discontinuation treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The presence of certain psychiatric symptoms has been associated with an increased likelihood of experiencing more severe withdrawal symptoms, which can present challenges to successful completion of BZD tapering.59,84”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [84]
In the citing paper
“The development of more severe BZD withdrawal symptoms is associated with use of BZDs with a shorter half-life and fewer active metabolites (e.g., alprazolam), daily use, higher total daily dose, longer duration of use, and history of severe withdrawal.69,79,84”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [84]
In the citing paper
“For example, patients with higher levels of anxiety may have more difficulty with tapering, and patients who exhibit traits associated with borderline, histrionic, or narcissistic personality disorder often experience considerable difficulty discontinuing BZDs (see “Patients with Co-occurring Psychiatric Disorders”).84”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [84]
In the citing paper
“Studies have shown that treatment for longer periods with high-dosage, short-acting BZD contribute to more severe withdrawal effects [61].”
From Benzodiazepines: Uses, Dangers, and Clinical Considerations (2021) · cites this paper as [61]
In the citing paper
“Milder effects are seen with longer-acting BZD that are used for shorter periods [61].”
From Benzodiazepines: Uses, Dangers, and Clinical Considerations (2021) · cites this paper as [61]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Tabachnick, B. G., & Fidell, L. S. (1983) · Cited by 80,042
SAUNDERS, J. B., AASLAND, O. G., BABOR, T. F., DE LA FUENTE, J. R., & GRANT, M. (1993) · Addiction · doi:10.1111/j.1360-0443.1993.tb02093.x · Cited by 13,597 · cited 1×
“…excluded if they required inpatient treatment for alcohol dependence, assessed as an Alcohol Use Disorders Identification Test (AUDIT) score of over 30 (Saunders et al., 1993), had active medical illnesses or psychosis, or had had illicit drug abuse or dependence (DSM-III-R) during the past year.”
MethodHealth Measurement Scales: A Practical Guide to Their Development and Use
Streiner, D. L., Norman, G. R., & Cairney, J. (1989) · Cited by 9,595
SCL-90: an outpatient psychiatric rating scale--preliminary report.
Derogatis, L. R., Lipman, R. S., & Covi, L. (1973) · PubMed · Cited by 4,633
Regier, D. A. (1990) · JAMA · doi:10.1001/jama.1990.03450190043026 · Cited by 3,962 · cited 1×
“In the Epidemiologic Catchment Area (ECA) study, the lifetime prevalence of sedativetranquillizer use disorders was estimated to be 1.2% (Regier et al., 1990).”
BackgroundInfluential(2024) · Pharmacological Reviews · doi:10.1124/pr · Cited by 2,664
The American Journal of Psychiatry
(2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp · Cited by 2,554
GOSSOP, M., DARKE, S., GRIFFITHS, P., HANDO, J., POWIS, B., HALL, W., & STRANG, J. (1995) · Addiction · doi:10.1046/j.1360-0443.1995.9056072.x · Cited by 1,343 · cited 1×
“The Severity of Dependence Scale (SDS) assesses psychological components of dependence, with higher scores indicating higher levels of dependence (range 0–15) (Gossop et al., 1995).”
BackgroundKushner, M. (2000) · Clinical Psychology Review · doi:10.1016/s0272-7358(99)00027-6 · Cited by 781 · cited 1×
“A two-way association between psychiatric disorders and substances use disorders has been recognized in epidemiologic and genetic epidemiologic studies (Kushner et al., 2000; Merikangas et al., 1998; Swendsen and Merikangas, 2000).”
BackgroundComorbidity of substance use disorders with mood and anxiety disorders
Merikangas, K. R., Mehta, R. L., Molnar, B. E., Walters, E. E., Swendsen, J. D., Aguilar-Gaziola, S., Bijl, R., Borges, G., Caraveo-Anduaga, J. J., Dewit, D. J., et al. (1998) · Addictive Behaviors · doi:10.1016/s0306-4603(98)00076-8 · Cited by 725
Research works printed but not linked: 7
- Ciraulo D. A., 1998, American Journal of Psychiatry, 145, 1501
- de l as, 2002, Addiction, 95, 245
- Derogatis L. R., 1973, Psychopharmacology Bulletin, 9, 13
- Gossop M., 1995, Addiction, 90, 607, 10.1111/j.1360-0443.1995.tb02199.x · DOI · Paper page
- Rickels K., 1988, Psychopharmacology Bulletin, 24, 415
- Spitzer R., 1985, Structured Clinical Interview for DSM-III-R, Patient Version
- Spitzer R., 1990, Structured Clinical Interview for DSM-III-R Personality Disorders (SCID-II)
Cited by
Benzodiazepines: Uses, Dangers, and Clinical Considerations
Edinoff, A. N., Nix, C. A., Hollier, J., Sagrera, C. E., Delacroix, B. M., Abubakar, T., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2021) · Neurology International · doi:10.3390/neurolint13040059 · Cited by 340
“Studies have shown that treatment for longer periods with high-dosage, short-acting BZD contribute to more severe withdrawal effects [61].”
BackgroundPsychosocial interventions for benzodiazepine harmful use, abuse or dependence
Darker, C. D., Sweeney, B. P., Barry, J. M., Farrell, M. F., & Donnelly-Swift, E. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009652.pub2 · Cited by 142
Sweetman, A., Putland, S., Lack, L., McEvoy, R. D., Adams, R., Grunstein, R., Stocks, N., Kaambwa, B., Van Ryswyk, E., Gordon, C., et al. (2021) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2020.101404 · Cited by 62
Chapoutot, M., Peter-Derex, L., Bastuji, H., Leslie, W., Schoendorff, B., Heinzer, R., Siclari, F., Nicolas, A., Lemoine, P., Higgins, S., et al. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph181910222 · Cited by 59
Brunner, E., Chen, C.-Y. A., Klein, T., Maust, D., Mazer-Amirshahi, M., Mecca, M., Najera, D., Ogbonna, C., Rajneesh, K. F., Roll, E., et al. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09499-2 · Cited by 51
Metadata
- Authors
- VORMA, H., NAUKKARINEN, H. H., SARNA, S. J., & KUOPPASALMI, K. I.
- Affiliations
- A-Clinic Foundation (FI)
- Helsinki University Hospital (FI)
- University of Helsinki (FI)
- Venue
- Substance Use & Misuse
- Publisher
- Informa UK Limited
- Published
- 2005-01
- Volume
- 40
- Issue
- 4
- Pages
- 499-510
- ISSN
- 1082-6084 (ISSN-L)
- 1532-2491
- OpenAlex
- W2018262147
- Cited by
- 22
- References
- 39
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 1 · 2021: 2 · 2020: 1 · 2019: 1 · 2018: 2 · 2017: 1 · 2016: 1 · 2015: 1 · 2014: 3
- FWCI
- 0.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Substance Use & Misuse (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alkoholitutkimussäätiö
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Keywords
- benzodiazepine dependence, benzodiazepine discontinuation, predictors of treatment outcome, cluster B personality disorders, borderline personality disorder, alcoholism, treatment discontinuation, personality disorder comorbidity
- MeSH terms
- Adult, Alcoholism, Anticonvulsants, Benzodiazepines, Diazepam, Female, Humans, Male, Personality Disorders, Quality of Life, Surveys and Questionnaires, Severity of Illness Index, Time Factors, Substance-Related Disorders, Diagnostic and Statistical Manual of Mental Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.